Madrigal Pharmaceuticals, Inc.
MDGL$5.10B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWEST CONSHOHOCKEN528 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Aug 4, 2026
7wMarket Overview
Stock performance and key metrics
MDGL News
Catalyst Timeline
4 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Resmetirom | Phase 3 | NASH | - | - |
MGL-3196 | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
NASH
1 drug in this indication
Heterozygous Familial Hypercholesterolemia
1 drug in this indication
Non-Alcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply